Hydroxyprogesterone

Hydroxyprogesterone

SCHEMBL23456341

CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C.CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 1.00
SHBG P04278 6/20 1.00
CYP2C19 P33261 5/20 1.00
SERPINA6 P08185 5/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
NR3C1 P04150 4/20 1.00
BLM P54132 4/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
MAPT P10636 2/20 1.00
ADORA3 P0DMS8 1/20 1.00
MAPK3 P27361 1/20 1.00
SLC6A3 Q01959 1/20 1.00
HIF1A Q16665 5/20 0.78
HSD17B10 Q99714 4/20 0.78
TSHR P16473 4/20 0.78
PMP22 Q01453 3/20 0.78
CYP3A4 P08684 2/20 0.78
ALDH1A1 P00352 3/20 0.74
PGR P06401 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydroxyprogesterone SCHEMBL8068 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2
Hydroxyprogesterone SCHEMBL30657985 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2
Hydroxyprogesterone SCHEMBL18261234 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2
Hydroxyprogesterone SCHEMBL265609 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2
Hydroxyprogesterone SCHEMBL13558389 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2
Hydroxyprogesterone SCHEMBL24287585 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2
Hydroxyprogesterone SCHEMBL3931615 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2
Hydroxyprogesterone SCHEMBL14523053 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2
Hydroxyprogesterone SCHEMBL14546356 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2
Hydroxyprogesterone SCHEMBL27048177 1.00 LMNA (1.00) LMNASHBGCYP2C19SERPINA6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240130980-A1 COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS Ilera Derm LLC 2024-04-25 US disclosed
US-11931452-B2 Topical compositions containing rofecoxib and methods of making and using the same JF PHARMA TECH LLC (US) 2024-03-19 US disclosed
US-11890260-B2 Compositions for treating acne and dermatological conditions Ilera Derm LLC (US) 2024-02-06 US disclosed
EP-4153306-A1 COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS Ilera Derm LLC (US) 2023-03-29 EP disclosed
US-20230025960-A1 TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME JLABS Beauty LLC (US) 2023-01-26 US disclosed
US-11260023-B2 Topical compositions containing rofecoxib and methods of making and using the same BRIORI BIOTECH, LLC (US) 2022-03-01 US disclosed
US-20210361591-A1 COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS Ilera Derm LLC 2021-11-25 US disclosed
WO-2021237214-A1 COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS Ilera Derm LLC (US) 2021-11-25 WO disclosed
US-20210220259-A1 TOPICAL COMPOSITIONS CONTAINING ROFECOXIB AND METHODS OF MAKING AND USING THE SAME ESTRATO PHARMA INC 2021-07-22 US disclosed
US-20210169759-A1 TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME JLABS Beauty LLC 2021-06-10 US disclosed
WO-2021113083-A1 TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME JLABS Beauty LLC (US) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11890260-B2 Compositions for treating acne and dermatological conditions COQ8A, ATP5ME, AGK LMNA 3710/4885SHBG 1514/4885CYP2C19 541/4885
US-20230025960-A1 TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME RXRG, CNR2, CUTA LMNA 1593/4885SHBG 95/4885CYP2C19 1258/4885
US-20210169759-A1 TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAME RXRG, CNR2, CUTA LMNA 1593/4885SHBG 95/4885CYP2C19 1258/4885
US-20210361591-A1 COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS COQ8A, ATP5ME, AGK LMNA 3710/4885SHBG 1514/4885CYP2C19 541/4885
US-20240130980-A1 COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS COQ8A, ATP5ME, AGK LMNA 3710/4885SHBG 1514/4885CYP2C19 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.